GATA1 mutations in down syndrome: Implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia

Pediatric Blood and Cancer

Volumn 44, Issue 1, 2005, Pages 40-44

  Crispino, John D ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Acute megakaryoblastic leukemia; Down syndrome; Transient myeloproliferative disorder

Indexed keywords

CD61 ANTIGEN; FIBRINOGEN RECEPTOR; HYBRID PROTEIN; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR RUNX1;

ACUTE MEGAKARYOCYTIC LEUKEMIA; AMINO TERMINAL SEQUENCE; ANEMIA; CANCER REGRESSION; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION; DNA ISOLATION; DOWN SYNDROME; EMBRYO DEVELOPMENT; ERYTHROPOIESIS; GENE DELETION; GENE EXPRESSION; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; HEMATOPOIESIS; HUMAN; LEUKEMOGENESIS; MEGAKARYOCYTE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; REVIEW; THROMBOCYTOPENIA; TRISOMY 21;

CHILD; DNA-BINDING PROTEINS; DOWN SYNDROME; ERYTHROID-SPECIFIC DNA-BINDING FACTORS; GATA1 TRANSCRIPTION FACTOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKEMIA, MEGAKARYOCYTIC, ACUTE; MUTATION; MYELOPROLIFERATIVE DISORDERS; RISK FACTORS; TRANSCRIPTION FACTORS;

EID: 10044294000     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20066     Document Type: Review

References (30)

1. Lange B. The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol 2000;110:512-524.
2. Zipursky A. Transient leukaemia - A benign form of leukaemia in newborn infants with trisomy 21. Br J Haematol 2003;120:930-938.
3. Al-Kasim F, Doyle JJ, Massey GV, et al. Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study. J Pediatr Hematol Oncol 2002;24:9-13.
4. Gurbuxani S, Vyas P, Crispino JD. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood 2004;103:399-406.
5. McDevitt MA, Shivdasani RA, Fujiwara Y. et al. A "knockdown" mutation created by cis-element gene targeting reveals the dependence of erythroid cell maturation on the level of transcription factor GATA-1. Proc Natl Acad Sci USA 1997;94:6781-6785.
6. Shivdasani RA, Fujiwara Y, McDevitt MA, et al. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J 1997;16:3965-3973.
7. Takahashi S, Komeno T, Suwabe N, et al. Role of GATA-1 in proliferation and differentiation of definitive erythroid and megakaryocytic cells in vivo. Blood 1998:92:434-442.
8. Vyas P, Ault K, Jackson CW, et al. Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood 1999;93:2867-2875.
9. Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 2002;32:148-152.
10. Groet J, McElwaine S, Spinelli M, et al. Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder. Lancet 2003;361:1617-1620.
11. Hitzler JK, Cheung J, Li Y, et al. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood 2003;101:4301-4304.
12. Mundschau G, Gurbuxani S, Gamis AS, et al. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood 2003;101:4298-4300.
13. Rainis L, Bercovich D, Strehl S, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood 2003;102:981-986.
14. Xu G, Nagano M, Kanezaki R, et al. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood 2003;102:2960-2968.
15. Calligaris R, Bottardi S, Cogoi S, et al. Alternative translation initiation site usage results in two functionally distinct forms of the GATA-1 transcription factor. Proc Natl Acad Sci USA 1995;92:11598-11602.
16. Robertson M, De Jong G, Mansvelt E. Prenatal diagnosis of congenital leukemia in a fetus at 25 weeks' gestation with Down syndrome: Case report and review of the literature. Ultrasound Obstet Gynecol 2003;21:486-489.
17. Smrcek JM, Baschat AA, Germer U, et al. Fetal hydrops and hepatosplenomegaly in the second half of pregnancy: A sign of myeloproliferative disorder in fetuses with trisomy 21. Ultrasound Obstet Gynecol 2001;17:403-409.
18. Stark B, Jeison M, Preudhomme C, et al. Acquired trisomy 21 and distinct clonal evolution in acute megakaryoblastic leukaemia in young monozygotic twins. Br J Haematol 2002;118:1082-1086.
19. Ahmed M, Sternberg A, Hall G, et al. Natural history of GATA1 mutations in Down Syndrome. Blood 2004;103:2480-2489.
20. Greaves MF, Wiemel J. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer 2003;3:639-649.
21. Higuchi M, O'Brien D, Kumaravelu P, et al. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 2002;1:63-74.
22. Mori H, Colman SM, Xiao Z, et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci USA 2002;99:8242-8247.
23. Ito E, Kasai M, Hayashi Y, et al. Expression of erythroid-specific genes in acute megakaryoblastic leukaemia and transient myeloproliferative disorder in Down's syndrome. Br J Haematol 1995;90:607-614.
24. Ito E, Kasai M, Toki T, et al. Expression of erythroid-specific genes in megakaryoblastic disorders. Leuk Lymphoma 1996;23:545-550.
25. Taub JW, Ravindranath Y. Down syndrome and the transient myeloproliferative disorder: Why is it transient? J Pediatr Hematol Oncol 2002;24:6-8.
26. Gamis AS, Woods WG, Alonzo TA. et al. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: A report from the Children's Cancer Group Study 2891. J Clin Oncol 2003;21:3415-3422.
27. Ravindranath Y. Down syndrome and acute myeloid leukemia: The paradox of increased risk for leukemia and heightened sensitivity to chemotherapy. J Clin Oncol 2003;21:3385-3387.
28. Sieweke MH, Graf T. A transcription factor party during blood cell differentiation. Curr Opin Genet Dev 1998;8:545-551.
29. Cantor AB, Orkin SH. Transcriptional regulation of erythropoiesis: An affair involving multiple partners. Oncogene 2002;21:3368-3376.
30. Look AT. A leukemogenic twist for GATAI. Nat Genet 2002;32:83-84.